A patient with 17 primary tumours and a germ line mutation in TP53: Tumour induction by adjuvant therapy?

Clinical Oncology

Volumn 12, Issue 5, 2000, Pages 300-304

  Nutting, C ^a   Camplejohn, R S ^b   Gilchrist, R ^b   Tait, D ^a   Blake, P ^a   Knee, G ^c   Yao, W Q ^a   Ross, G ^a   Fisher, C ^a   Eeles, R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c KINGSTON HOSPITAL   (United Kingdom)

Author keywords

Carcinogenesis; Li Fraumeni syndrome; Radiotherapy; Tamoxifen; TP53

Indexed keywords

CYTOSINE; DNA; PROTEIN P53; TAMOXIFEN; THYMINE;

ADULT; AGING; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CASE REPORT; DNA DAMAGE; DNA REPAIR; ENDOMETRIUM CANCER; ENVIRONMENTAL EXPOSURE; FAMILIAL CANCER; FEMALE; GENE DELETION; GENE MUTATION; GENOTOXICITY; GERM LINE; HUMAN; MULTIPLE CANCER; MUTATION RATE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0033709501     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2000.9179     Document Type: Article

References (24)

1. Kirsch DG, Kastan MB. Tumour suppressor p53: implications for tumour development and prognosis. J Clin Oncol 1998;16:3158-68.
2. Frebourg T, Barbier N, Yan YX, et al. Germ line p53 mutations in 15 families with the Li-Fraumeni syndrome. Am J Hum Genet 1995;56:608-15.
3. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990;30:1233-8.
4. Varley JM, McGown G, Thorcroft M, et al. Germ line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997;57:3245-52.
5. Camplejohn RS, Perry P, Hodgson SV, et al. A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. Br J Cancer 1995;72:654-62.
6. Eeles RA, Warren W, Knee G, et al. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 1993;8:1269-76.
7. Gowen LC, Avrutskaya AV, Latour AM, et al. BRCA1 required for transcription coupled repair of oxidative DNA damage. Science 1998;281:1009-12.
8. Boice JD, Harvey EB, Blettner M, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326:781-5.
9. Kyle RA. Second malignancies associated with chemotherapy. In: Perry MC, Yarbro YW, editors. Toxicity of chemotherapy. New York: Grune and Stratton, 1984;479-506.
10. King CM. Tamoxifen and the induction of cancer. Carcinogenesis 1995;16:1449-54.
11. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339:1-15.
12. Some pharmaceutical drugs. (IARC monographs on the evaluation of carcinogenic risks to humans, vol. 66.) Lyon: IARC, 1996.
13. Piver MS, Hempling MD. A prospective trial of post-operative vaginal radium-caesium for Grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for Grade 3 or deep myometrial invasion in surgical Stage I endometrial adenocarcinoma. Cancer 1990;66:1133-8.
14. Hemminki K, Rajaniemi H, Lindahl B, et al. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 1996;56:4374-7.
15. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutuation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52:6194-9.
16. Shiseki M, Nishikawa R, Yamamoto H, et al. Germ line p53 mutation is uncommon in patients with triple primary cancers. Cancer Lett 1993;73:51-7.
17. Scott RJ, Krummenacher F, Mary JL, et al. Hereditary p53 mutuation in a patient with multiple tumours: significance for genetic counseling. Schweiz Med Wochenschr 1993;123:1287-92.
18. Mazoyer S, Lalle P, Moyret-Lalle C, et al. Two germ line mutations affecting the same nucleotide at codon 257 of p53 gene: a rare site for mutations. Oncogene 1994;9:1237-9.
19. Gutierrez MI, Bhatia KG, Barreiro C, et al. A de novo p53 germline mutation affecting codon 151 in a six-year-old child with multiple tumors. Hum Mol Genet 1994;3:2247-8.
20. Kyritsis AP, Bondy ML, Xiao M, et al. Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst 1994;86:344-9.
21. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
22. Varley JM, McGown G, Thorncroft M, et al. A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene 1996;12:2437-42.
23. Speiser P, Gharehbaghi-Schnell E, Eder S, et al. A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer 1996;74:269-73.
24. Sedlacek Z, Kodet R, Poustka A, et al. A database of germline p53 mutations in cancer-prone families. Nucleic Acids Res 1998;26:214-5.